TOTAL

Padova
group

Udine
group

Cancer site/type
(ICD-10)

Obs.
Tot. (PD/UD)

IR
*100.000

SIR

95% CI

 

SIR (95% CI)

 

SIR (95% CI)

 

 

 

 

 

 

 

Head and neck (C00-14 and 30, 32)

7(4/3)

231.4

4.6

1.3-11.9

4.4 (0.5-16.1)

4.8 (0.6-17.5)

Esophagus (C15)

5 (3/2)

171.8

18.7

3.9-54.7

12.1 (0.3-67.6)

25.7 (3.1-92.9)

Stomach (C16)

3(2/1)

171.3

4.3

0.9-12.6

5.6 (0.7-20.4)

2.9 (0.1-16.4)

Colon (C18)

2(2/0)

114.9

2.5

0.3-9.2

5.2 (0.6-18.8)

NC

Lung (C34)

4 (2/2)

114.2

0.9

0.1-3.2

0.9 (0.0-4.8)

0.9 (0.0-5.2)

Melanoma of skin (C43)

2 (1/1)

114.4

10.1

1.2-36.3

9.5 (0.2-53.2)

10.6 (0.3-59.2)

Kaposi’s sarcoma (C46)

6 (6/0)

291.5

211.6

68.7-493.8

370.2 (120.2-863.9)

NC

Breast, female (C50)

1(0/1)

193.3

1.2

0.0-6.7

NC

2.1 (0.1-12.0)

Cervix uteri (C53)

2 (2/0)

192.8

12.8

0.3-71.4

28.1 (0.7-156.5)

NC

Non Hodgkin’s Lymphoma (C82-85,C96)

8 (3/5)

286.7

13.7

4.5-32.0

10.7 (1.3-38.7)

16.9 (3.5-49.3)

 

 

 

 

 

 

 

All cancers but skin

40 (25/15)

1822.1

3.0

2.0-4.3

4.0 (2.4-6.2)

2.1 (1.1-3.8)

NC: the SIR was not computed because no cancer cases were observed
Table 3: incidences rates (IR) (*100.000) and standardized incidence ratios (SIR) with 95% confidence intervals (CI) according to cancer site/type and transplant.